Centric Wealth Management Sells 90,514 Shares of Pfizer Inc. $PFE

Centric Wealth Management decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 74.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,866 shares of the biopharmaceutical company’s stock after selling 90,514 shares during the quarter. Centric Wealth Management’s holdings in Pfizer were worth $761,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in PFE. Citizens National Bank Trust Department increased its holdings in Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after buying an additional 395 shares in the last quarter. Peak Asset Management LLC lifted its stake in Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after acquiring an additional 402 shares during the period. Community Bank & Trust Waco Texas boosted its holdings in shares of Pfizer by 0.6% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after acquiring an additional 412 shares during the last quarter. Able Wealth Management LLC grew its stake in shares of Pfizer by 2.0% in the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock worth $512,000 after acquiring an additional 413 shares during the period. Finally, CVA Family Office LLC raised its holdings in shares of Pfizer by 3.3% during the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after purchasing an additional 413 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 1.2%

NYSE PFE opened at $26.43 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $150.24 billion, a P/E ratio of 15.36 and a beta of 0.47. The stock’s 50-day moving average price is $25.52 and its 200-day moving average price is $25.03.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s payout ratio is 100.00%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla is doubling down on oncology with a roughly $23 billion post‑COVID investment plan, positioning Pfizer as a major growth bet on cancer therapies — a strategic pivot investors see as a multi‑year revenue driver. ‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology
• Positive Sentiment: Pfizer struck a non‑exclusive licensing agreement to access Novavax’s Matrix‑M adjuvant technology (reported value ~$530M), which could boost future vaccine efficacy and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix‑M Adjuvant Technology
• Positive Sentiment: A bullish technical/forecast note projects upside toward ~$36.16, which can attract momentum and speculative buying. PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside
• Neutral Sentiment: Pfizer is due to report Q4 and full‑year 2025 results before the market opens Feb. 3; consensus Q4 estimates cited are ~$16.9B sales and $0.57 EPS — the upcoming print is the near‑term catalyst. Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
• Neutral Sentiment: Zacks and other outlets report heightened retail/investor attention on PFE and provide deeper metric estimates ahead of earnings — increased search/coverage can amplify moves on the print. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Background pieces (portfolio company lists, Wall Street metric breakdowns) add context but are unlikely to move the stock materially on their own. 7 Companies Owned by Pfizer
• Negative Sentiment: Critical commentary warns of valuation and execution risks (Seeking Alpha: “Buyer Beware”) and highlights that risks may outweigh near‑term rewards, which can pressure sentiment. Pfizer: Buyer Beware, The Risk Outweighs The Reward
• Negative Sentiment: Media coverage of past management tactics (CEO comments on extreme COVID-era measures) and notes that PFE has recently underperformed peers may feed governance/PR concerns and short‑term selling. Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19 Pfizer Inc. stock underperforms Wednesday when compared to competitors

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PFE. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. TD Cowen restated a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Zacks Research cut Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Finally, Bank of America cut their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.